Insights

Strategic Collaborations CRISPR Therapeutics has established collaborations with leading companies like Bayer and Vertex Pharmaceuticals, providing an opportunity to leverage these partnerships for potential cross-selling or joint ventures.

Upcoming Human Trials With plans to launch human trials for CTX450 in 2025, there is a potential opportunity to engage with healthcare institutions, research organizations, and clinical trial partners for collaboration and product adoption.

Investment Interest Recent investments from Wealthcare Advisory Partners LLC and Kingswood Group indicate growing investor interest in CRISPR Therapeutics, presenting an opportunity to engage with financial firms and high-net-worth individuals for strategic partnerships or funding.

Key Personnel Addition The addition of Christian Rommel, Ph.D., to CRISPR Therapeutics' Board of Directors brings valuable expertise in gene-based medicine development, opening avenues to connect with key opinion leaders and experts in the biotechnology field for collaborations and knowledge sharing.

Genome Editing Focus CRISPR Therapeutics' specialization in developing therapies for genetic disorders using CRISPR/Cas9 technology presents a unique value proposition for engaging with pharmaceutical companies, research institutions, and healthcare providers interested in innovative gene-based treatments.

CRISPR Therapeutics Tech Stack

CRISPR Therapeutics uses 8 technology products and services including Qubit, Docker, Cloudflare, and more. Explore CRISPR Therapeutics's tech stack below.

  • Qubit
    A/B Testing
  • Docker
    Containerization
  • Cloudflare
    Content Management System
  • AngularJS
    Javascript Frameworks
  • Modernizr
    Javascript Libraries
  • Microsoft Azure
    Platform As A Service
  • Boomi
    Platform As A Service
  • Python
    Programming Languages

Media & News

CRISPR Therapeutics's Email Address Formats

CRISPR Therapeutics uses at least 1 format(s):
CRISPR Therapeutics Email FormatsExamplePercentage
first.last@crisprtx.comJohn.Doe@crisprtx.com
89%
flast@crisprtx.comJDoe@crisprtx.com
8%
last@crisprtx.comDoe@crisprtx.com
2%
first.l@crisprtx.comJohn.D@crisprtx.com
1%

Frequently Asked Questions

Where is CRISPR Therapeutics's headquarters located?

Minus sign iconPlus sign icon
CRISPR Therapeutics's main headquarters is located at 105 West First Street Boston, MA 02127 US. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is CRISPR Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact CRISPR Therapeutics's main corporate office by phone at +41-61-228-78-00. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is CRISPR Therapeutics's stock symbol?

Minus sign iconPlus sign icon
CRISPR Therapeutics is a publicly traded company; the company's stock symbol is CRSP.

What is CRISPR Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
CRISPR Therapeutics's official website is crisprtx.com and has social profiles on LinkedIn.

How much revenue does CRISPR Therapeutics generate?

Minus sign iconPlus sign icon
As of May 2024, CRISPR Therapeutics's annual revenue reached $75M.

What is CRISPR Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
CRISPR Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does CRISPR Therapeutics have currently?

Minus sign iconPlus sign icon
As of May 2024, CRISPR Therapeutics has approximately 451 employees across 6 continents, including North AmericaEuropeAsia. Key team members include Chief Financial Officer: R. P.Chief Medical Officer: N. P.Chief Operating Officer: J. B.. Explore CRISPR Therapeutics's employee directory with LeadIQ.

What industry does CRISPR Therapeutics belong to?

Minus sign iconPlus sign icon
CRISPR Therapeutics operates in the Biotechnology Research industry.

What technology does CRISPR Therapeutics use?

Minus sign iconPlus sign icon
CRISPR Therapeutics's tech stack includes QubitDockerCloudflareAngularJSModernizrMicrosoft AzureBoomiPython.

What is CRISPR Therapeutics's email format?

Minus sign iconPlus sign icon
CRISPR Therapeutics's email format typically follows the pattern of . Find more CRISPR Therapeutics email formats with LeadIQ.

How much funding has CRISPR Therapeutics raised to date?

Minus sign iconPlus sign icon
As of May 2024, CRISPR Therapeutics has raised $280M in funding. The last funding round occurred on Feb 13, 2024.

When was CRISPR Therapeutics founded?

Minus sign iconPlus sign icon
CRISPR Therapeutics was founded in 2013.
CRISPR Therapeutics

CRISPR Therapeutics

Biotechnology ResearchMassachusetts, United States201-500 Employees

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Section iconCompany Overview

Headquarters
105 West First Street Boston, MA 02127 US
Phone number
+41-61-228-78-00
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
CRSP
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
201-500

Section iconFunding & Financials

  • $280M

    CRISPR Therapeutics has raised a total of $280M of funding over 6 rounds. Their latest funding round was raised on Feb 13, 2024.

  • $50M$100M

    CRISPR Therapeutics's revenue is in the range of $50M$100M

Section iconFunding & Financials

  • $280M

    CRISPR Therapeutics has raised a total of $280M of funding over 6 rounds. Their latest funding round was raised on Feb 13, 2024.

  • $50M$100M

    CRISPR Therapeutics's revenue is in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.